| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 董事会关于独立董事独立性情况的专项意见 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（ 以下简称（ 公司"）董事会根据（ 上市公 司独立董事管理办法》 深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等要求，并结合公司在任独立董事黄建春先生、李学尧先 生、李丹蒙先生分别出具的（ 独立董事独立性自查情况表》，对三位独立董事的 独立性情况进行了评估，并出具如下意见： 经核查独立董事黄建春先生、李学尧先生、李丹蒙先生的任职经历以及出具 的（ 独立董事独立性自查情况表》，上述人员不存在任何妨碍其进行独立客观判 断的关系，不存在影响独立董事独立性的情况，符合（ 上市公司独立董事管理办 法》 深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》中关于独立董事的任职资格及独立性的要 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2025-049 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召 开第五届董事会第二十五次会议和第五届监事会第十五次会议，审议通过了《关 于会计政策变更的议案》。本次会计政策变更系公司根据法律法规和国家统一的 会计制度的要求进行的变更，无需提交公司股东大会审议，现将本次会计政策变 更的相关事项公告如下： 一、本次会计政策变更情况概述 1、变更原因 2024年12月，财政部发布《关于印发<企业会计准则解释第 18 号>的通知》 （财会【2024】24 号）对"关于不属于单项履约义务的保证类质量保证的会计处 理"进行了解释，该解释自印发之日起施行，允许企业自发布年度提前执行。 本次会计政策变更后，公司将按《企业会计准则解释第 18 号》相关规定执 行，其他未变更部分，仍按照财政部 ...

国投证券股份有限公司 关于上海雪榕生物科技股份有限公司 2024 年度内部控制自我评价报告的核查意见 国投证券股份有限公司（以下简称"国投证券"或"本保荐机构"）作为上海雪 榕生物科技股份有限公司（以下简称"雪榕生物"或"公司"）创业板向特定对象发 行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等相关规定，对《上海雪榕生物科技股份有限公司 2024 年度内部控制自我评价报告》进行了核查，相关核查情况及核查意见如下： 一、保荐机构进行的核查工作 国投证券保荐代表人通过与雪榕生物的董事、监事、高级管理人员及内部审 计人员等相关人员交谈，列席公司股东大会、董事会，查阅雪榕生物的股东大会、 董事会、监事会等会议文件以及各项业务和管理规章制度，从雪榕生物的内部控 制环境、内部控制制度、内部控制程序、内部控制的监督等方面对其内部控制的 完整性、合理性及有效性进行了核查。 二、公司对内部控制的总体评价 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准 日，不存在财务报告内部控制重大缺陷 ...

上海雪榕生物科技股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2025]0011004169 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 上海雪榕生物科技股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 上海雪榕生物科技股份有限公司 2024 年度非 经营性资金占用及其他关联资金往来情况汇 总表 1 三、 事务所及注册会计师执业资质证明 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 控股股东及其他关联方 资金占用情况的专项说明 大华核字[2025]0011004169 号 上海雪榕生物科技股份有限公司全体股东： 我们接受委托， ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2025-051 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于召开 2024 年年度股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）第五届董事会第二十 五次会议审议通过了《关于召开 2024 年年度股东大会的议案》，决定于 2025 年 5 月 23 日召开公司 2024 年年度股东大会，现将本次股东大会的有关事项通知如 下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024 年年度股东大会。 2、股东大会召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2025 年 5 月 23 日 14:30，现场会议以现场和网络 视频相结合的方式召开； （2）网络投票时间：2025 年 5 月 23 日，其中： ①通 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2025-053 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 第五届监事会第十五次会议决议公告 上海雪榕生物科技股份有限公司（以下简称"公司"）第五届监事会第十五次 会议通知于 2025 年 4 月 14 日以电子邮件等方式通知全体监事，并于 2025 年 4 月 25 日在公司会议室举行，采取现场与通讯相结合的方式进行表决。本次会议 应到监事 3 名，实到 3 名。公司保荐代表人聂晓春女士、黄璇女士列席会议。会 议由监事会主席胡卫红女士主持。 本次会议的召开符合《公司法》《公司章程》及有关法律、法规的规定。 二、监事会会议审议情况 1、审议通过《关于 2024 年度监事会工作报告的议案》 具体内容详见公司公布在中国证监会指定创业板信息披露网站巨潮资讯网 的《2024 年度监事会工作报告》。 本议案以 3 票同意，0 票反对，0 票弃权获得通过。 本议案尚需提交公司股东大会审议批准。 2、审议通过《关于 2024 年年度报告及其摘要的议案》 本公司及监事会全体成员保证信息披露 ...

Financial Performance - In 2024, the company achieved operating revenue of 2,162.45 million yuan, a year-on-year decrease of 15.70%, and reported a net loss attributable to shareholders of 617.07 million yuan[5]. - The main reason for the loss was the weak overall consumer market, intense competition in the edible mushroom industry, and a decrease in product prices due to supply-demand imbalance[5]. - The company's operating revenue for 2024 was ¥2,162,449,367.04, a decrease of 15.70% compared to ¥2,565,144,194.86 in 2023[36]. - The net profit attributable to shareholders for 2024 was -¥617,070,813.21, representing a decline of 228.12% from -¥188,062,576.34 in 2023[36]. - The total assets at the end of 2024 were ¥3,854,555,536.98, down 16.24% from ¥4,602,166,751.34 at the end of 2023[36]. - The total equity attributable to shareholders decreased by 39.62% to ¥938,628,711.97 at the end of 2024 from ¥1,554,529,572.05 at the end of 2023[36]. - The company has reported a negative net profit for the most recent fiscal year, indicating ongoing financial challenges[37]. - The gross profit margin for the edible mushroom industry decreased to 2.31%, down 4.98% year-over-year[72]. Production and Capacity - The company continues to focus on the research and development, cultivation, and sales of fresh edible mushrooms, including varieties such as enoki mushrooms and shiitake mushrooms[6]. - As of 2024, the total production capacity of the edible mushroom industry in China exceeded 10,000 tons per day, with enoki mushrooms accounting for 50.68% of the production capacity among the top five varieties[8]. - The company has a daily production capacity of 1,680 tons of edible mushrooms, with 1,275 tons of that being enoki mushrooms, leading the industry in China[50]. - The company has established eight major production bases in China and a production base in Thailand, indicating a strategic national and international expansion[50]. Market Strategy and Competition - The company plans to strengthen marketing efforts and improve product quality to maintain market share amid increasing competition and declining prices[12]. - The overall consumption market in 2024 is expected to remain weak, leading to intensified competition and supply-demand imbalance in the edible mushroom industry[58]. - The company has implemented a sales model primarily through distributors, with a focus on direct sales to supermarkets and fresh food delivery platforms[58]. - The company plans to pause large capital expenditures and focus on stabilizing production and sales in response to market conditions[68]. Research and Development - The company has been selected as a key laboratory for mushroom strain research by the Ministry of Agriculture and Rural Affairs, highlighting its technological leadership[66]. - The company owns 45 patents, including 13 invention patents, and has been recognized as a key enterprise in agricultural industrialization[66]. - The company is focused on maintaining strict control over food safety throughout the entire production and distribution process[21]. Financial Management and Governance - The company is initiating a stock issuance project in March 2025 to enhance its debt repayment capacity and provide sufficient funding for future operations[11]. - The company has established a comprehensive food safety management system to mitigate food safety risks associated with raw material procurement and distribution[21]. - The company has a dedicated financial accounting department and an independent financial decision-making system, ensuring financial autonomy[116]. - The company has a strategic committee that reviews major investment and financing plans, ensuring due diligence in capital operations[111]. Employee and Talent Management - The total number of employees at the end of the reporting period is 2,112, with 1,292 in production, 447 in technical roles, and 77 in sales[146][147]. - The company has established a dual-channel talent development system, focusing on both general and elite talent training[150]. - The company has implemented various training programs, including new employee orientation and professional skills training, to enhance employee capabilities[150]. Social Responsibility and Environmental Commitment - Snow Rong Bio actively engages in social responsibility initiatives, including participation in poverty alleviation and community development projects[170]. - The company has been recognized for its contributions to poverty alleviation, receiving awards for its efforts in building mushroom precision poverty alleviation industrial parks[170]. - The company’s environmental management system meets relevant standards and regulatory requirements, ensuring effective control[168]. Shareholder Commitments and Rights - The company commits to repurchase all newly issued shares if it fails to fulfill its obligations, with the repurchase price determined by the higher of the issuance price or the secondary market price[173]. - The company will disclose any failure to fulfill commitments and the reasons for such failures in a timely manner[175]. - The commitments made by the company will take effect immediately upon signing and cannot be changed or revoked unless there are changes in relevant laws or regulations[176].

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2025-039 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 第五届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长杨勇萍先生召集，会议通知于 2025 年 4 月 14 日以 电子邮件等通讯方式发出。 2、本次董事会于 2025 年 4 月 25 日在上海雪榕生物科技股份有限公司（以 下简称"公司"）会议室召开，采取现场和通讯相结合的方式进行表决。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长杨勇萍先生主持，公司监事、高级管理人员和公司 保荐代表人聂晓春女士、黄璇女士列席了本次董事会。 5、本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规 及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于 2024 年总经理工作报告的议案》 本议案以 7 票同意，0 票反对，0 票弃权获得 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 1、公司 2024 年度利润分配预案为：不派发现金红利，不送红股，不以资本 公积金转增股本。 2、公司利润分配预案不触及《深圳证券交易所创业板股票上市规则》第 9.4 条第（八）项规定的可能被实施其他风险警示情形。 一、审议程序 上海雪榕生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日 召开第五届董事会独立董事专门会议第五次会议、第五届董事会第二十五次会议 和第五届监事会第十五次会议，分别以全票赞成的结果审议通过了《关于公司 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年年度股东大会审 议批准。 1、独立董事专门会议意见 鉴于公司 2024 年度发生亏损，公司 2024 年度利润分配预案符合《公司法》 《公司章程》等有关规定，与公司当前实际情况相符。同意公司 2024 年度利润 分配预案，并提交公司董事会审议。 2、董事会意见 上海雪榕生物科技股份有限公司 关于 2024 年度 ...

Financial Performance - The company's revenue for Q1 2025 was ¥440,692,931.37, a decrease of 27.04% compared to ¥603,985,503.43 in the same period last year[5] - Total operating revenue decreased to ¥440,692,931.37 from ¥603,985,503.43, representing a decline of approximately 27%[22] - Total operating costs decreased to ¥440,694,795.18 from ¥602,081,762.76, a reduction of about 27%[22] - Net profit for the period increased to ¥12,248,024.25 compared to ¥10,702,846.50, showing an increase of approximately 14%[23] - Net profit attributable to shareholders increased by 38.20% to ¥7,242,399.82 from ¥5,240,339.19 year-on-year[5] Cash Flow and Liquidity - The net cash flow from operating activities rose by 8.12% to ¥86,083,523.69 compared to ¥79,620,418.03 in the previous year[5] - Operating cash inflow for the current period was $437,465,747.80, a decrease of 30% from $625,262,991.86 in the previous period[25] - Net cash flow from operating activities increased to $86,083,523.69, up from $79,620,418.03, representing a growth of 5.8%[25] - Cash outflow from investing activities was $21,139,903.61, significantly lower than $225,133,378.38 in the previous period, indicating a reduction of 90.6%[25] - Net cash flow from investing activities improved to -$14,803,661.38 from -$211,239,268.15, showing a positive change of 93%[25] - Cash inflow from financing activities totaled $147,590,000.00, down 82.8% from $859,525,881.17 in the previous period[26] - Net cash flow from financing activities was -$176,816,188.35, a decline from $622,031,168.28, reflecting a decrease of 128.4%[26] - The ending cash and cash equivalents balance decreased to $44,392,997.38 from $647,061,490.68, a drop of 93.2%[26] - The company's cash and cash equivalents decreased from 167,953,803.72 yuan to 44,780,056.33 yuan, a decline of approximately 73.3%[19] Assets and Liabilities - Total assets decreased by 4.50% to ¥3,681,036,326.42 from ¥3,854,555,536.98 at the end of the previous year[5] - The total assets decreased to ¥3,681,036,326.42 from ¥3,854,555,536.98, a decline of about 4.5%[21] - Total liabilities decreased significantly, with a notable drop in contract liabilities by 73.29% to ¥5,508,558.48 from ¥20,620,117.76[8] - Total liabilities decreased to ¥2,609,403,210.59 from ¥3,031,232,610.38, a reduction of approximately 13.9%[21] - The total non-current assets decreased from 3,000,000,000 yuan to approximately 2,900,000,000 yuan, reflecting a decline of about 3.3%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,338[13] - The largest shareholder, Yang Yongping, holds 19.53% of the shares, totaling 107,606,850 shares[13] - The total number of restricted shares held by Yang Yongping remains at 80,705,137 shares due to executive lock-up regulations[15] - The company has not disclosed any other related party relationships among shareholders[14] Research and Development - Research and development expenses decreased by 66.68% to ¥505,920.27 from ¥1,518,369.89 year-on-year[9] - Research and development expenses decreased to ¥505,920.27 from ¥1,518,369.89, a decline of approximately 67%[22] Other Income and Comprehensive Income - The company recorded a 39.17% increase in other income, amounting to ¥3,450,029.09 compared to ¥2,479,024.48 in the same period last year[9] - The company reported a comprehensive income total of ¥12,186,978.16, slightly up from ¥12,125,088.65, indicating stable performance[23] Corporate Actions - The company signed a framework agreement for a change of control with Shanghai Wanzihong Intelligent Technology Co., Ltd., which will result in a change of the controlling shareholder[16] - The company plans to issue new shares to specific investors as part of the control change agreement[16] Accounting Standards - The company did not execute any new accounting standards adjustments for the current reporting period[27]